April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Long-Term Outcome of Common AMD Treatment Protocols
Author Affiliations & Notes
  • D. S. Dyer
    Retina Associates, PA, Kansas City, Missouri
  • M. P. Ellis
    Retina Associates, PA, Kansas City, Missouri
  • L. D. Dyer
    Retina Associates, PA, Kansas City, Missouri
  • Footnotes
    Commercial Relationships  D.S. Dyer, Eyetech, Inc., R; Genentech, R; M.P. Ellis, None; L.D. Dyer, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 512. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. S. Dyer, M. P. Ellis, L. D. Dyer; Long-Term Outcome of Common AMD Treatment Protocols. Invest. Ophthalmol. Vis. Sci. 2010;51(13):512.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To assess the recurrence rate of choroidal neovascularization in AMD patients treated for 24 months of continued anti-VEGF therapy.

Methods: : A retrospective review was conducted of the charts of all patients treated in a retinal referral practice with intravitreal injections of anti-VEGF agents for neovascular AMD. All patients treated for > 24 months were included. Treatment regimen, visual acuity at each visit, total number of injections and duration of therapy were recorded for each patient. Following cessation of treatment patients were examined at a minimum of three month intervals to monitor for the development of recurrent choroidal neovascularization following cessation of anti-VEGF therapy.

Results: : 314 patients with NV-AMD treated with intravitreal injections from 7/14/04 to 7/24/09 were eligible for inclusion in the review. All patients received an initial period of "induction" with monthly injections of either bevacizumab or ranibizumab. Once the neovascular complex was felt to be regressed, an extended regimen with an anti-VEGF antagonist was initiated. Two treatment patterns were identified that received extended anti-VEGF therapy, Induction/Maintenance (n=171) and Treat and Extend (n=143). 46.3% of patients developed recurrent CNV within two years after treatment stopped. 63.1% of the recurrences occurred within the first year after the cessation of treatment.

Conclusions: : Patients treated with intravitreal injections of an anti-VEGF antagonist at consistent interval for an extended time period retained visual gains achieved by the induction therapy. PRN therapy produced a steady decline in vision throughout the extended phase of treatment/follow-up. Induction therapy followed by maintenance injections of pegaptanib produced the largest visual gains during the extended period. Those receiving the T&E regimen showed a trend toward better visual results with more frequent injections. Longer treatment intervals with T&E (> 8 weeks) placed patients at risk for greater visual loss. Patients treated at 6 week intervals with either pegaptanib or ranibizumab during the extended phase of treatment had the best visual gains at the end of 24 months of treatment.

Keywords: age-related macular degeneration • retina • choroid: neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.